Muscle loss Loss of muscle has become a significant topic of discussion around GLP-1 medications
Srenson's thinking was coloured by the fact that a previous drug, Redux, approved in 1996 by the FDA for weight loss and launched with great fanfare, had to be withdrawn a year later after it was found to cause major heart attacks and to be largely ineffective
J Clin Endocrinol Metab (2002) 87(3):123946
These multifaceted metabolic effects position dual GLP-1/GIP receptor agonists as superior therapeutic candidates for MASLD, especially in patients with coexisting obesity and T2DM, where dysregulated glucose and lipid metabolism drive the progression of the disease
As more evidence becomes available on the GLP-1s, expect the halo impact on overlapping comorbidities to accelerate their adoption
Common during caloric deficit, especially in the first few weeks